npg

REVIEW

Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2

Hyun Lee[1], Peter L Whitfeld[2] and Charles R Mackay[1,2]

Complement component C5a is one of the most potent inflammatory chemoattractants and has been implicated in the pathogenesis of numerous inflammatory diseases. C5a binds two receptors, C5aR and C5L2. Most of the C5a functional effects occur through C5aR, and the pharmaceutical industry has focused on this receptor for the development of new anti-inflammatory therapies. We used a novel approach to generate and test therapeutics that target C5aR. We created human C5aR knock-in mice, and used neutrophils from these to immunize wild-type mice. This yielded high-affinity blocking mAbs to human C5aR. We tested these anti-human C5aR mAbs in mouse models of inflammation, using the human C5aR knock-in mice. These antibodies completely prevented disease onset and were also able to reverse established disease in the K/B×N arthritis model. The physiological role of the other C5a receptor, C5L2 is still unclear, and our studies with blocking mAbs to human C5L2 have failed to demonstrate a clear functional role in signaling to C5a. The development of effective mAbs to human C5aR is an alternative approach to drug development, for this highly attractive target.

The complement system plays an essential role in innate immunity, and production of one of the pathway components, C5a, is particularly important for recruitment of immune cells and effective clearance of infectious agents. However, the detrimental effects of uncontrolled C5a production have been implicated in various pathological conditions making C5a and its receptors attractive targets for therapeutic intervention for inflammatory diseases. Mice genetically deficient in one of the receptors for C5a (C5aR) and antagonists that inhibit C5a signaling have established that the blocking C5a or its receptors holds enormous promise for treatment of various autoimmune diseases and acute inflammatory conditions. This review will outline recent findings on the biology of the two receptors for C5a, C5aR and C5L2, and the rationale for development of new anti-inflammatory agents that inhibit C5aR or C5L2 function.

THE COMPLEMENT SYSTEM AND THE GENERATION OF C5a
The complement system is an ancient defense mechanism that facilitates phagocytosis and clearance of pathogens. It is a biochemical cascade, comprising more than 20 serum proteins that normally circulate as inactive forms. Complement can be activated by four different pathways: the classical pathway, the alternative pathway, the lectin pathway[1] and, the recently discovered, extrinsic protease pathway.[2] Regardless of how the pathway is activated, the cascade leads to the generation of one of the most important effector molecules, C5a.

The classical pathway is initiated by C1q binding to immune complexes of complement fixing IgG1 and IgM on the surface of pathogens. The lectin pathway is activated independently of immunoglobulin, by serum protein mannose-binding lectin, which directly recognizes carbohydrate structures on bacterial and viral surfaces. The lectin pathway is very similar to the classical pathway except for the initial recognition and activation step, and, importantly, all the pathways converge to generate C5 convertase. C5 convertase from the classical and alternative pathways (C4bC2aC3b and C3bC3bBb, respectively) cleaves C5 into C5a and C5b. C5b binds to C3b and initiates the formation of the membrane attack complex, which leads to cell lysis and bacterial killing (reviewed in Ricklin and Lambris[1] and Ward[3]). Recently, there have been additional activation pathways identified, which give rise to C5a. An extrinsic protease pathway involves direct cleavage of C3 and C5 by a series of proteolytic enzymes such as kallikrein[4] and thrombin.[2] Thrombin can directly activate and cleave C5 to yield biologically active C5a in mice genetically deficient in C3, in which C5 convertase cannot be formed.[2] The final products of complement activation—C3a, C4a and C5a—were referred to as anaphylatoxins because of their ability to trigger degranulation of mast cells, basophils and neutrophils. Of these, C5a is the most effective mediator of leukocyte degranulation or chemotaxis, and represents one of the most potent inflammatory molecules produced during immune responses.

C5a STRUCTURE AND FUNCTION

Nuclear magnetic resonance spectroscopy shows the structure of human C5a to be a four-helix bundle; the four α-helical segments juxtapose in an antiparallel topology, which are stabilized by three disulfide bonds (Cys21-Cys47, Cys22-Cys54 and Cys34-Cys55) and connected by three peptide loops.[5–7] The flexible carboxyl terminal tail (aa 69–74 MQLGR) forms a helical turn that is connected by a short loop (reviewed in Monk *et al.*[8]), which is important for effector functions of C5a. When this region is missing, C5a still binds to the receptor but loses agonistic activity.[9] This and other data support a 'two-site binding' model for C5a–C5aR interaction.[10] The model suggests that the N terminus and disulphide-linked core region of C5a interact with a 'recognition site' that includes both the N terminus and the third extracellular loop of C5aR, and the C-terminal region of C5a fits into a binding pocket around the fifth transmembrane region, called the 'effector site.'[10,11] This model explains why C5a without the C-terminal region loses full effector function, even though it binds to the receptor.

C5a is one of the most potent inflammatory peptides and shows diverse activities on many cell types. Depending on the cell type, C5a signaling can lead to various outcomes including phagocytosis, degranulation, H_2O_2 production, granule enzyme release, delay or enhancement of apoptosis, chemokine and cytokine production, and chemotaxis. Table 1 summarizes the pleiotropic functions of C5a for different cell types.

Once C5a is cleaved from C5, plasma enzyme carboxypeptidases rapidly metabolize C5a by removing the C-terminal arginine to form 'C5a desArg.'[29,30] C5a desArg has a reduced potency, ∼10–1000 times compared with C5a depending on the its function.[31] The K_d of C5a and C5a desArg binding to C5aR is estimated at 1 and 412–660 nM, respectively.[32,33] Both C5a and C5a desArg are cleared from body fluids very quickly. When ^{125}I-C5a or ^{125}I-C5a desArg are injected intravenously into adult rabbits, more than 50% of the injected radioactivity for both mediators is cleared from the circulation within 2 min and accumulates in highly vascularized organs such as lung, liver and spleen.[34] This rapid removal of C5a from circulation is

believed to be due to the binding of C5a to receptors for C5a on leukocytes. When purified granulocytes or monocytes were added to complement-activated plasma *in vitro*, up to 80% of C5a was removed from plasma and C5aR-blocking antibody inhibited C5a clearance.[35] Notably, when C5aR internalization and recycling in granulocytes was blocked by treating leukocytes with the ionophore monensin, C5a was still cleared from plasma indicating that rather than ligand-receptor internalization, binding of C5a to the receptor on leukocytes is important in C5a removal from the circulation.[35]

RECEPTORS FOR C5a: C5aR AND C5L2

The potent inflammatory functions of C5a (see Table 1) indicate that inhibition of this ligand, or its receptor(s), might alleviate certain inflammatory conditions. There are two receptors known to bind to C5a; C5aR (CD88) and C5L2 (GPR77). Both are seventh transmembrane proteins and their genes are located on chromosome 19, q13.33–13.34 (human) directly neighboring each other. They cluster together with the genes for other closely related chemoattractant receptors such as formyl-peptide receptors FPRH1 and FPRH2.[36] C5aR was the first anaphylatoxin receptor to be cloned, in 1991.[37,38] In contrast, C5L2 was cloned much later, in 2000, by PCR amplification using degenerate primers based on amino-acid sequences known to be conserved in chemoattractant receptors.[39] The C5L2 sequence shows closest identity to that of C5aR (58%) and C3aR (55%).[40,41]

C5a and C5a desArg have been reported as ligands for C5L2.[41] Okinaga *et al.*[33] performed competitive ligand-binding assays with ^{125}I-C5a in cell lines transfected with human C5aR or C5L2. They showed that C5a bound to both C5aR and C5L2 with high affinity (K_d 3.4 and 2.5 nM, respectively). C5a desArg bound to C5aR with greatly reduced affinity (660 nM) compared with C5a, but it bound to C5L2 with affinity as high as C5a (12 nM). Whether C3a and C3a desArg serve as ligands for C5L2 is uncertain, as different laboratories have produced conflicting data.[33,42,43]

The functional role of a receptor is intimately associated with the cell types upon which it is expressed. C5aR was initially thought to be expressed mainly on leukocytes such as neutrophils, eosinophils, basophils, monocytes, dendritic cells and mast cells, but it is now established that C5aR can be widely expressed, on both immune and nonimmune cells. Reported nonimmune cell that express C5aR include vascular endothelial cells,[44] cardiomyocytes,[45] astrocytes,[46] microglia,[47] neural stem cells,[48] oligodendrocytes,[49] synoviocytes,[50] articular chondrocytes,[51] renal glomerular mesangial cells,[52] hepatic kupfer cells and stimulated hepatocytes,[53–55] bronchial epithelial cells[56] and keratinocytes.[57] C5aR shows a dramatic pattern of regulation, especially in tissues from mice undergoing the cecal ligation/puncture sepsis model.[58] C5aR immunoreactivity was strikingly increased in lung, liver, kidney and heart in the cecal ligation/puncture model.

C5L2 is expressed at much lower levels on both immune and nonimmune cells, compared with C5aR. C5L2 is expressed on neutrophils, macrophages,[59] immature dendritic cells[39] and some nonimmune type cells such as adipocytes and skin fibroblasts,[60] as well as adrenal gland, spinal cord, thyroid, liver, lung, spleen, brain and heart.[61] In our studies, we have raised highly specific monoclonal antibodies (mAbs) to human C5L2 and confirmed that C5L2 in humans is expressed on neutrophils and other nonlymphoid cells, but at levels considerably less than that of C5aR (H Lee and CR Mackay, unpublished). These mAbs should be useful in establishing the precise pattern of C5L2 expression and regulation in tissues, particularly where expression may deviate from that of C5aR, such as in adipose tissue.

Table 1 Functional activity of C5a on different cell types

Cell type	Activity
Neutrophils	Enhanced expression of adhesion molecules[12]
	Chemotaxis[13]
	Oxidative burst (O_2 consumption)[14]
	Phagocytosis[14]
	Release of granule enzymes[15]
	Delayed apoptosis[16]
Eosinophils	Release of granule enzymes[17,18]
	Chemotaxis[19]
Basophils	Histamine release[20]
Mast cells	Histamine secretion[20]
	Chemotaxis[21]
Plasmacytoid dendritic cells	Chemotaxis[22]
Macrophages/monocytes	Chemotaxis[23]
	Cytokine release[24]
Thymocytes	Enhances apoptosis[25]
Endothelium	Vasodilation[26]
	Chemokine release[26]
Hepatocytes	Enhanced regeneration[27]
Microglia	Chemotaxis[28]

C5a RECEPTORS: STRUCTURE AND SIGNALING PROPERTIES

Both C5aR and C5L2 are seven transmembrane proteins that belong to rhodopsin-like family. Although these two receptors share structural similarity, there are several important differences. C5aR signaling pathways have been studied extensively. C5aR couples to pertussis toxin-sensitive $G_{i\alpha2}$, $G_{i\alpha3}$[62] or pertussis toxin-insensitive $G_{\alpha16}$[63] and initiates several downstream signaling pathways (reviewed in Johswich and Klos[64]). Signaling of C5aR involves intracellular calcium mobilization, and activation of different pathways such as phosphatidylinositol-bisphosphate-3-kinase/Akt (also known as protein kinase-B; PKB),[65] Ras/B-Raf/mitogen-activated protein kinase/extracellular signal-related kinase,[66] phospholipase D (PLD),[67] protein kinase C,[66] p21-activated kinases, which are downstream effectors of cdc42 and rac GTPases,[68] signal transducers and activators of transcription, sphingosine kinase[69] and NF-κB.[70] In neutrophils, C5a activates phosphatidylinositol-bisphosphate-3-kinase to phosphorylate Akt, and subsequently Bad protein is phosphorylated and prevents pro-apoptotic caspase 9 activation resulting in inhibition of apoptosis.[65] C5a protects neurons from glutamate-induced apoptosis through mitogen-activated protein kinase-mediated regulation of caspase 3.[71] PLD activated by C5a produces phosphatidic acid and diglyceride in neutrophils. PLD is known to control many neutrophil functions, such as the oxidative response, degranulation, chemotaxis and protease release.[72] C5a also results in extracellular signal-related kinase phosphorylation downstream of RAS/RAF signaling and causes nicotinamide adenine dinucleotide phosphate (reduced form) oxidase assembly and results in reactive oxygen species production in rat alveolar macrophages.[73] Mitogen-activated protein kinase inhibitor PD98059 and SB203580 and phosphatidylinositol-bisphosphate-3-kinase inhibitor wortmannin and LY294002 inhibit C5a-induced migration of macrophages,[74] indicating an important role for the mitogen-activated protein kinase and phosphatidylinositol-bisphosphate-3-kinase pathways in chemotaxis. C5a stimulates the generation of sphingosine-1-phosphate and sphingosine kinase-1 activity in human macrophages, and knocking down sphingosine kinase-1 using antisense oligonucleotides abolishes C5a-induced intracellular calcium signals, degranulation, cytokine production and chemotaxis.[69] In neutrophils, C5a activates IκBα, which suppresses NF-κB, whereas in macrophages C5a actuates NF-κB and leads to cytokine and chemokine production (reviewed in Guo et al.[75]). In human HEK293 cells, C5a induces signal transducers and activators of transcription phosphorylation both at Tyr^{705} and Ser^{727} residues through the activation of PTX-insensitive $G_{\alpha16}$ protein, and Ras/Raf/MEK/extracellular signal-related kinase and c-Src/JAK pathways are involved.[76]

DISSECTING THE ROLE OF THE ENIGMATIC C5a RECEPTOR, C5L2

Unlike C5aR, C5L2 has been regarded, until recently, as a nonfunctional decoy receptor. Okinaga et al.[33] showed that when the murine B cell line L1.2-expressing C5L2 was treated with C5a, there was no mobilization of intracellular calcium, extracellular signal-related kinase phosphorylation or receptor internalization, in contrast to C5aR expressing cells, which responded to C5a as expected. Moreover, they examined mRNA expression after C5a treatment of bone marrow cells from C5aR-deficient mice to probe effects of C5L2 signaling on transcription and found no detectable C5a-mediated changes in gene expression. Similarly, RBL-2H3 cells transfected with C5L2 did not show any intracellular calcium mobilization, degranulation or receptor internalization upon C5a binding,[41] and HL-60 and U937 cell lines, which endogenously express C5L2 showed similar results in calcium

mobilization.[42] It has been suggested that the inability of C5L2 to signal is due to the change in a highly conserved 'DRY (Asp-Arg-Tyr) motif' located at amino-acid residues 137–139 near the third transmembrane domain, which is highly conserved in many GPCRs. The central arginine residue of this motif has been shown to be important in receptor coupling to G proteins.[77] C5L2 has DLC (Asp-Leu-Cys) in the motif and when central leucine was mutated to arginine, C5a could induce a small increase in intracellular calcium levels in 293 T cells co-expressing $G_{\alpha16}$, suggesting that leucine at residue 132 in C5L2 contributes to G protein uncoupling.[33] Other differences in the C5L2 structure, compared with C5aR, are the lack of the NPXXY (Asn-Pro-X-X-Tyr) motif in the seventh transmembrane domain and a shorter third intracellular loop lacking the conserved basic region and serine/threonine residues, which are thought to be potential protein kinase C phosphorylation sites[41] (reviewed in Monk et al.[8]).

In 2005, Gao et al.[61] reported that in a rat model of sepsis following cecal ligation/puncture, mRNA and protein levels for C5L2 increased in lung and liver and blocking C5L2 with an anti-C5L2 antibody dramatically increased the level of the inflammatory cytokine IL-6 in serum. Similar results were obtained by Gerard et al.[78] from mice genetically deficient in C5L2. They found that mice lacking C5L2 showed enhanced responses to both C5a and C5a desArg, suggesting an anti-inflammatory function for C5L2.

All of the above data supported the notion that C5L2 is a nonsignaling receptor and that it serves as a decoy, similar to a number of other nonsignaling decoy chemoattractant receptors. However, recent data now suggest a functional positive regulatory role of C5L2 for C5a signalling.[59] Using another C5L2-deficient mouse strain, Chen et al. showed that these mice were hypersensitive to lipopolysaccharide-induced septic shock and showed reduced airway hyperresponsiveness and inflammation in an ovalbumin-induced model. We have attempted to resolve these discrepancies through another approach—use of C5L2 antagonistic mAbs. We produced a mAb that completely antagonizes C5a binding to C5L2 transfectants. In our hands, the anti-C5L2 mAb did not significantly inhibit neutrophil chemotaxis to C5a (H Lee, Y Lim and CR Mackay, unpublished). Moreover, anti-C5aR mAbs completely blocked neutrophil chemotaxis to C5a, suggesting that C5aR was the predominant, if not the only, receptor for chemotactic responses to C5a. Likewise in a phagocytosis assay in vitro, anti-C5aR mAb completely blocked neutrophil phagocytosis, whereas anti-C5L2 mAb showed no effect (unpublished). Hopefully, mAbs will be developed that recognize and block mouse C5L2, and these should help resolve the in vivo relevance of this receptor.

ROLE OF C5a AND ITS RECEPTORS IN INFLAMMATORY DISEASES

As C5a is such a potent pro-inflammatory mediator, it is very important to control expression to allow rapid responses to pathogens, but at the same time protection for the host against unregulated overactivity.[1] When this tightly regulated balance is disrupted, overproduction of C5a can occur, leading to uncontrolled inflammation. Excessive production of C5a can downregulate immune responses in some leukocytes, and, at the same time, it can overactivate other cell types. For example, when high levels (10–100 nM) of C5a are present in plasma, neutrophils become functionally paralyzed and demonstrate defective phagocytosis and reduced generation of H_2O_2, loss of chemotactic responses to C5a and end up losing bacteria-killing effect.[79–81] On the other hand, high levels of C5a potentiate macrophage responses to lipopolysaccharide, to produce excessive levels of pro-inflammatory mediators such as TNF-α and various other

156

chemokines[82] leading to uncontrolled inflammation. On endothelial cells, high levels of C5a leads to enhanced production of pro-inflammatory mediators such as IL-8, IL-1β and RANTES,[83] and tissue factor, which serves as a cofactor for blood coagulation.[84]

Overproduced C5a or upregulated C5aR expression has been implicated in the pathogenesis of many inflammatory conditions, autoimmune and neurodegenerative diseases. These include rheumatoid arthritis,[85–87] respiratory distress syndrome,[88] inflammatory bowel diseases,[89] glomerulonephritis,[90] systemic lupus erythematosus,[91] ischemia/reperfusion injury,[92] chronic obstructive pulmonary disease,[93] sepsis,[79] multiple sclerosis,[94] asthma and allergy,[95] atherosclerosis,[96] xenograft rejection,[97] hemorrhagic shock[98,99] and antiphospholipid syndrome.[100]

DEVELOPMENT OF INHIBITORS OF C5a/C5aR SIGNALING

Over the past decades, even before the discovery of C5aR, many groups have tried to develop highly potent and specific small molecule antagonists to block C5a function. This has turned out to be surprisingly difficult, probably because C5a has a relatively high molecular weight ($>10\,000$) and blocking large protein–protein interactions with small molecules can be difficult, especially if the interaction involves multiple sites. Nevertheless, in recent years a few potent antagonists for C5aR have been developed[101] including nonpeptidic small molecules,[102,103] C5a mutants,[104] short peptides[105] and cyclic peptides,[106–108] mAbs and antibody fragments.[109–112]

NON-PEPTIDE C5aR ANTAGONISTS

Nonpeptide small molecular weight antagonists that can be easily administered orally have been developed. Merck identified series of chemical compounds, which were effective antagonists for C5aR but because of unwanted agonistic activity, they were not developed further.[102] Mitsubishi Pharma Corporation (Yokohama, Japan) developed an orally active nonpeptide C5aR antagonist W-54011. W-54011 inhibits ^{125}I-labeled C5a to human neutrophils, intracellular calcium mobilization, chemotaxis and generation of reactive superoxide species without showing agonistic activity up to 10 μM. Neurogen reported a nonpeptide antagonist NDT9520492, which contains a three-ring structure[103] and a similar compound NGD 2000-1 was tested in human clinical trials for the treatment of rheumatoid arthritis. Phase I studies of NGD 2000-1 showed that it inhibited cytochrome P450 (3A4), a metabolic enzyme found in the liver, which metabolizes many drugs (reviewed in Monk et al.[8] and Sumichika[113]). Development of NGD 2000-1 has been abandoned.

C5a MUTANTS AND ANTAGONISTIC PEPTIDES FOR C5aR

C5a$_{1–71}$T$_1$M,C$_{27}$S,Q$_{71}$C monomer (C5aRAM; CGS 27913) was developed by modifying the C-terminal region of human C5a.[104] C5aRAM and its dimer C5aRAD (CGS 32359) inhibit ^{125}I-C5a binding to human neutrophils, C5a-induced intracellular calcium mobilization, CD11b integrin upregulation, superoxide generation, lysozyme release and chemotaxis. In vivo, C5aRAM inhibited C5a-induced dermal edema in rabbits and C5a-induced neutropenia in micropigs.[104] Moreover, in a porcine model of surgical revascularization, when given intravenous (i.v.) injection before surgical procedure, C5aRAD significantly inhibited neutrophil activation and reduced infarct size.[114]

A novel recombinant C5aR antagonist ΔpIII-A8 was discovered by Heller et al.[115] by screening human C5a phage libraries in which the C terminus of C5a desArg was mutated. It inhibits binding of ^{125}I-hC5a to differentiated U-937 cells, C5a-induced chemotaxis and lysosomal enzyme release without agonistic activity. In the reverse passive Arthus reaction, i.v. injection of ΔpIII-A8 significantly inhibited polymorphonuclear leukocyte accumulation in the peritoneum, skin and the lung. In a model of intestinal ischemia/reperfusion injury, ΔpIII-A8 decreased tissue injury by reducing bowel wall edema, hemorrhage and pulmonary microvascular dysfunction.[115]

Peptide analogues of the C terminus of C5a were generated based on structure/activity studies. N-MePhe-Lys-Pro-D-cha-Trp-D-Arg (C-089) is a full antagonist and blocks C5a-induced degranulation and GTPase activity in human neutrophils.[105] Taylor's group used C-089 as a structural template and modified it to generate potent and selective C5a antagonists. A cyclic peptide, Phe-[Orn-Pro-D-Cha-Trp-Arg] (F-[OPdChaWR]), which showed high affinity for C5aR and inhibited ^{125}I-C5a binding and C5a-mediated myeloperoxidase release from human neutrophils.[106,107] They acetylated F-[OPdChaWR] to derive a new antagonist, AcF-[OPdChaWR], which inhibits ^{125}I-C5a binding to intact polymorphonuclear leukocytes with an IC$_{50}$ of 20 nM[108] (reviewed in Monk et al.[8] and Sumichika[113]). It inhibited C5a- and lipopolysaccharide-induced neutropenia and the reverse passive Arthus reaction in rats.[116] In a rat model of immune-mediated monoarticular arthritis, oral administration of AcF-[OPdChaWR] significantly reduced the severity of pathology such as swelling of knee, histopathology, gait disturbance and serum and intra-articular levels of inflammatory cytokines.[117] AcF-[OPdChaWR] also reduces pathological symptoms in other animal models of inflammatory diseases, such as ischemia/reperfusion injury,[118,119] inflammatory bowel diseases,[89] hemorrhagic shock,[98] lupus nephritis[120] and sepsis.[121] This compound has been evaluated in human clinical trials.[122]


Figure 1 Molecular representation of the surface of human C5aR with the binding site for inhibitory monoclonal antibodies (mAbs). The small region in the second extracellular loop of C5aR (EEYFPP) was the main target for blocking and inhibitory mAbs.[109] The picture was kindly provided by Søren Berg Padkjær (Novo Nordisk A/S) and was produced using the program MolSoft BrowserPro using a homology model based on alignment of C5aR sequence with rhodopsin. C5aR backbone (schematic), Epitope 'EEYFPP' (spacefilling). It is likely that this region in the second extracellular loop of C5aR plays a critical role, either as a second binding site for C5a and/or as a region that transmits a conformational change in receptor structure, that results in receptor signaling.

THERAPEUTIC mAbs TO C5aR

Monoclonal antibodies constitute a rapidly growing class of therapeutics due, in part, to their predictable pharmacokinetic properties, their high success rate in the clinic[123] and their ability to antagonize large protein–protein interactions. Moreover, developments in the production, humanization and engineering of mAbs[124] has resulted in more than 150 antibodies advancing to clinical development[125] with 22 antibodies have been approved by the FDA for therapeutic application.[123] Recently, an antibody against complement component C5 (Eculizumab; soliris) was approved by the FDA and represents the first complement-targeting drug that had been given marketing authorization.[1]

We have undertaken an extensive effort to develop therapeutic mAbs to hC5aR. mAbs to C5aR were raised using two approaches. First, we used a well-established approach[126] for raising mAbs to chemoattractant receptors, using L1.2 cells (a murine B cell lymphoma line) expressing very high levels of hC5aR ($\sim$80 000 receptors per cell).[109] In a second and perhaps more innovative approach, we immunized wild-type mice with neutrophils from hC5aR knock-in (KI) mice.[109] In this approach, wild-type mice should mount a focused response to hC5aR, since it will be the only antigen seen as foreign, and is expressed at very high levels on neutrophils, up to 200 000 molecules per cell.[127] Both approaches were successful in generating highly specific mAbs to hC5aR. mAbs generated through both of these approaches completely blocked C5a binding to its receptor, intracellular calcium mobilization and leukocyte chemotaxis, and showed no signs of agonist activity.[109]

Recent studies by us and others suggest a critical role for the second extracellular loop of the chemoattractant receptors in ligand binding,[109,128] receptor activation[129] and even in antagonist binding.[130] Of the many mAbs generated by us against hC5aR, all of the most potent inhibitors of C5a binding or function mapped to a very specific region in the second extracellular loop of C5aR.[109] The location of this region is shown in a predicted three-dimensional structural model of hC5aR (Figure 1), generated using the rhodopsin structure as a template and alignment of conserved C5aR residues. Similar mapping of function-blocking mAbs to the second extracellular loop have been reported for CCR5.[131]

Use of hC5aR KI mice provides an excellent example of how transgenic mice can be used for the in vivo evaluation of pharmacological agents such as therapeutic mAbs or small molecules. Use of human molecule KI mice is particularly useful for preclinical development of drugs that display selectivity for the human target. In our studies with anti-C5aR mAbs, we used hC5aR KI mice in a model of inflammatory arthritis. K/B×N inflammatory arthritis mediated by serum transfer was induced in hC5aR KI mice, and the preventative and therapeutic effect of mAb 7F3 were readily demonstrable.[109] The very rapid reversal of inflammation was likely due to blocking C5a and C5aR signaling and preventing neutrophil migration to the joint, rather than neutrophil depletion from the blood. C5aR is also expressed by mast cells and macrophages, both of which play a role in the K/B×N serum transfer model of arthritis. To our knowledge, there is no other treatment that is as effective at reversing inflammation in this model, besides anti-C5 treatment. However, anti-C5 blocking mAb required a much higher amount of mAb ($\sim$40 mg kg^{-1})[132] compared with anti-C5aR mAb (as low as $\sim$1 mg kg^{-1}). The reason for this may presumably relate to the high concentration ($\sim$170 µg ml^{-1}) of C5 that is normally present in blood and tissue fluids.[133] Blocking C5aR not only prevented synovitis, but also cartilage degradation in the K/B×N arthritis model.[109] Blocking C5aR might provide additional benefit to rheu-


Figure 2 Steps in the pathogenesis of rheumatoid arthritis, and the role of C5a and C5aR. Steps in the pathogenesis of rheumatoid arthritis may include the following: 1. Breakdown of T-cell and B-cell tolerance. This could occur due to a variety of genetic and environmental conditions, but ultimately results in the production of autoantibodies directed to self-proteins. 2. Deposit of antibody complexes in synovial tissue. 3. Activation of the complement pathway. In the K/B×N model of inflammatory arthritis, autoantibody deposition activates the alternative complement pathway, which leads to C5a production. C5a production serves to activate mast cells, and to recruit inflammatory cells to the joint, such as polymorphonuclear leukocytes (PMNs), mast cells and macrophages. 4. In human rheumatoid arthritis, the synovial membrane becomes hyperplastic and ultimately develops into a 'pannus,' which destroys the articular cartilage and underlying bone. The release of angiogenic factors, such as VEGF or angiogenic chemokines contributes to new blood vessel growth and continued inflammation. Release of inflammatory cytokines such as TNF, IL-1 and matrix metaloproteinases (MMPs) contribute to joint inflammation and destruction.

matoid arthritis patients, over its anti-inflammatory effects, as Onuma et al. reported that C5aR is expressed on human articular chondrocytes, and expression levels were significantly higher in rheumatoid arthritis patients than in control groups (26% in rheumatoid arthritis, 9.0% in osteoarthritis and 6.9% in normal). Moreover, IL-1β, which is known to have a catabolic effect on chondrocyte metabolism,[134,135] significantly enhances expression of C5aR on chondrocytes in rheumatoid arthritis and normal samples.[51] Also, it has been reported that local production of almost all of the complement components are found in joint tissue,[136] and levels of C5aR expression are also upregulated in inflammatory and proliferative synovial tissues.[85] These data suggest that C5aR may be directly involved in joint destruction in rheumatoid arthritis patients. A model summarizing the likely steps in the pathogenesis of rheumatoid arthritis, and the involvement of C5a and its receptors, is shown in Figure 2.

CONCLUSIONS

C5a and its receptors are attractive targets for therapeutic intervention in numerous inflammatory diseases. The appropriate indications for C5a–C5aR inhibition will emerge with the relevant human clinical trials, although studies in rodents suggest that antagonists of C5aR will find utility in a wide range of inflammatory diseases, particularly rheumatoid arthritis. The most effective way to inhibit C5aR is still to be resolved. We have developed blocking mAbs, since small molecule inhibitors have proven difficult for this receptor. Hopefully, anti-C5aR mAbs will enter human clinical trials in the coming years.

1 Ricklin D, Lambris JD. Complement-targeted therapeutics. *Nat Biotechnol* 2007; **25**: 1265–1275.
2 Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR *et al.* Generation of C5a in the absence of C3: a new complement activation pathway. *Nat Med* 2006; **12**: 682–687.
3 Ward PA. The dark side of C5a in sepsis. *Nat Rev* 2004; **4**: 133–142.
4 Thoman ML, Meuth JL, Morgan EL, Weigle WO, Hugli TE. C3d-K, a kallikrein cleavage fragment of iC3b is a potent inhibitor of cellular proliferation. *J Immunol* 1984; **133**: 2629–2633.
5 Zuiderweg ER, Fesik SW. Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a. *Biochemistry* 1989; **28**: 2387–2391.
6 Zhang X, Boyar W, Toth MJ, Wennogle L, Gonnella NC. Structural definition of the C5a C terminus by two-dimensional nuclear magnetic resonance spectroscopy. *Proteins* 1997; **28**: 261–267.
7 Zuiderweg ER, Nettesheim DG, Mollison KW, Carter GW. Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. *Biochemistry* 1989; **28**: 172–185.
8 Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. *Br J Pharmacol* 2007; **152**: 429–448.
9 Kohl J, Lubbers B, Klos A, Bautsch W, Casaretto M. Evaluation of the C-terminal C5a effector site with short synthetic C5a analog peptides. *Eur J Immunol* 1993; **23**: 646–652.
10 Siciliano SJ, Rollins TE, DeMartino J, Konteatis Z, Malkowitz L, Van Riper G *et al.* Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. *Proc Natl Acad Sci USA* 1994; **91**: 1214–1218.
11 Huber-Lang MS, Sarma JV, McGuire SR, Lu KT, Padgaonkar VA, Younkin EM *et al.* Structure–function relationships of human C5a and C5aR. *J Immunol* 2003; **170**: 6115–6124.
12 Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM *et al.* C5a-induced expression of P-selectin in endothelial cells. *J Clin Invest* 1994; **94**: 1147–1155.
13 Snyderman R, Pike MC. Chemoattractant receptors on phagocytic cells. *Annu Rev Immunol* 1984; **2**: 257–281.
14 Mollnes TE, Brekke O-L, Fung M, Fure H, Christiansen D, Bergseth G *et al.* Essential role of the C5a receptor in *E coli*-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. *Blood* 2002; **100**: 1869–1877.
15 Becker EL, Kermode JC, Naccache PH, Yassin R, Marsh ML, Munoz JJ *et al.* The inhibition of neutrophil granule enzyme secretion and chemotaxis by pertussis toxin. *J Cell Biol* 1985; **100**: 1641–1646.
16 Perianayagam MC, Balakrishnan VS, Pereira BJ, Jaber BL. C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and Bad-mediated signalling pathway. *Eur J Clin Invest* 2004; **34**: 50–56.
17 Takafuji S, Tadokoro K, Ito K, Dahinden CA. Degranulation from human eosinophils stimulated with C3a and C5a. *Int Arch Allergy Immunol* 1994; **104** (Suppl 1): 27–29.
18 Egesten A, Malm J. Eosinophil leukocyte degranulation in response to serum-opsonized beads: C5a and platelet-activating factor enhance ECP release, with roles for protein kinases A and C. *Allergy* 1998; **53**: 1066–1073.
19 DiScipio RG, Daffern PJ, Jagels MA, Broide DH, Sriramarao P. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration *in vitro* and *in vivo*. *J Immunol* 1999; **162**: 1127–1136.
20 Schulman ES, Post TJ, Henson PM, Giclas PC. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. *J Clin Invest* 1988; **81**: 918–923.
21 Hartmann K, Henz BM, Krüger-Krasagakes S, Köhl J, Burger R, Guhl S *et al.* C3a and C5a stimulate chemotaxis of human mast cells. *Blood* 1997; **89**: 2863–2870.
22 Gutzmer R, Köther B, Zwirner J, Dijkstra D, Purwar R, Wittmann M *et al.* Human plasmacytoid dendritic cells express receptors for anaphylatoxins C3a and C5a and are chemoattracted to C3a and C5a. *J Invest Dermatol* 2006; **126**: 2422–2429.
23 Marder SR, Chenoweth DE, Goldstein IM, Perez HD. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. *J Immunol* 1985; **134**: 3325–3331.
24 Okusawa S, Yancey KB, van der Meer JW, Endres S, Lonnemann G, Hefter K *et al.* C5a stimulates secretion of tumor necrosis factor from human mononuclear cells *in vitro*. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. *J Exp Med* 1988; **168**: 443–448.
25 Guo RF, Huber-Lang M, Wang X, Sarma V, Padgaonkar VA, Craig RA *et al.* Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. *J Clin Invest* 2000; **106**: 1271–1280.
26 Albrecht EA, Chinnaiyan AM, Varambally S, Kumar-Sinha C, Barrette TR, Sarma JV *et al.* C5a-induced gene expression in human umbilical vein endothelial cells. *Am J Pathol* 2004; **164**: 849–859.
27 Daveau M, Benard M, Scotte M, Schouft MT, Hiron M, Francois A *et al.* Expression of a functional C5a receptor in regenerating hepatocytes and its involvement in a proliferative signaling pathway in rat. *J Immunol* 2004; **173**: 3418–3424.
28 Yao J, Harvath L, Gilbert DL, Colton CA. Chemotaxis by a CNS macrophage, the microglia. *J Neurosci Res* 1990; **27**: 36–42.
29 Bokisch VA, Muller-Eberhard HJ. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. *J Clin Invest* 1970; **49**: 2427–2436.
30 Huey R, Bloor CM, Kawahara MS, Hugli TE. Potentiation of the anaphylatoxins *in vivo* using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. *Am J Pathol* 1983; **112**: 48–60.
31 Hugli TE, Muller-Eberhard HJ. Anaphylatoxins: C3a and C5a. *Adv Immunol* 1978; **26**: 1–53.
32 Marder SR, Chenoweth DE, Goldstein IM, Perez HD. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. *J Immunol* 1985; **134**: 3325–3331.
33 Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade MB *et al.* C5L2, a nonsignaling C5A binding protein. *Biochemistry* 2003; **42**: 9406–9415.
34 Webster RO, Larsen GL, Henson PM. *In vivo* clearance and tissue distribution of C5a and C5a des arginine complement fragments in rabbits. *J Clin Invest* 1982; **70**: 1177–1183.
35 Oppermann M, Gotze O. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. *Immunology* 1994; **82**: 516–521.
36 Bao L, Gerard NP, Eddy Jr RL, Shows TB, Gerard C. Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19. *Genomics* 1992; **13**: 437–440.
37 Boulay F, Mery L, Tardif M, Brouchon L, Vignais P. Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. *Biochemistry* 1991; **30**: 2993–2999.
38 Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. *Nature* 1991; **349**: 614–617.
39 Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi TA. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. *Mol Immunol* 2000; **37**: 407–412.
40 Lee DK, George SR, Cheng R, Nguyen T, Liu Y, Brown M *et al.* Identification of four novel human G protein-coupled receptors expressed in the brain. *Brain Res Mol Brain Res* 2001; **86**: 13–22.
41 Cain SA, Monk PN. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). *J Biol Chem* 2002; **277**: 7165–7169.
42 Johswich K, Martin M, Thalmann J, Rheinheimer C, Monk PN, Klos A. Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines. *J Biol Chem* 2006; **281**: 39088–39095.
43 Kalant D, Cain SA, Maslowska M, Sniderman AD, Cianflone K, Monk PN. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg^{77}/acylation-stimulating protein. *J Biol Chem* 2003; **278**: 11123–11129.
44 Laudes IJ, Chu JC, Huber-Lang M, Guo RF, Riedemann NC, Sarma JV *et al.* Expression and function of C5a receptor in mouse microvascular endothelial cells. *J Immunol* 2002; **169**: 5962–5970.
45 Niederbichler AD, Hoesel LM, Westfall MV, Gao H, Ipaktchi KR, Sun L, Zetoune FS *et al.* An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. *J Exp Med* 2006; **203**: 53–61.
46 Gasque P, Chan P, Fontaine M, Ischenko A, Lamacz M, Götze O *et al.* Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. *J Immunol* 1995; **155**: 4882–4889.
47 Lacy M, Jones J, Whittemore SR, Haviland DL, Wetsel RA, Barnum SR. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. *J Neuroimmunol* 1995; **61**: 71–78.
48 Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I, Nilsson AK *et al.* Complement: a novel factor in basal and ischemia-induced neurogenesis. *EMBO J* 2006; **25**: 1364–1374.
49 Nataf S, Levison SW, Barnum SR. Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage. *Brain Res* 2001; **894**: 321–326.
50 Yuan G, Wei J, Zhou J, Hu H, Tang Z, Zhang G. Expression of C5aR (CD88) of synoviocytes isolated from patients with rheumatoid arthritis and osteoarthritis. *Chin Med J (Engl)* 2003; **116**: 1408–1412.
51 Onuma H, Masuko-Hongo K, Yuan G, Sakata M, Nakamura H, Kato T *et al.* Expression of the anaphylatoxin receptor C5aR (CD88) by human articular chondrocytes. *Rheumatol Int* 2002; **22**: 52–55.
52 Braun M, Davis III AE. Cultured human glomerular mesangial cells express the C5a receptor. *Kidney Int* 1998; **54**: 1542–1549.
53 Koleva M, Schlaf G, Landmann R, Götze O, Jungermann K, Schieferdecker HL. Induction of anaphylatoxin C5a receptors in rat hepatocytes by lipopolysaccharide *in vivo*: mediation by interleukin-6 from Kupffer cells. *Gastroenterology* 2002; **122**: 697–708.
54 Schieferdecker HL, Schlaf G, Jungermann K, Gotze O. Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. *Int Immunopharmacol* 2001; **1**: 469–481.
55 Schlaf G, Schmitz M, Rothermel E, Jungermann K, Schieferdecker HL, Götze O. Expression and induction of anaphylatoxin C5a receptors in the rat liver. *Histol Histopathol* 2003; **18**: 299–308.
56 Floreani AA, Heires AJ, Welniak LA, Miller-Lindholm A, Clark-Pierce L, Rennard SI *et al.* Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke. *J Immunol* 1998; **160**: 5073–5081.
57 Fayyazi A, Sandau R, Duong LQ, Götze O, Radzun HJ, Schweyer S *et al.* C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. *Am J Pathol* 1999; **154**: 495–501.

58 Riedemann NC, Guo RF, Laudes IJ, Keller K, Sarma VJ, Padgaonkar V et al. C5a receptor and thymocyte apoptosis in sepsis. *FASEB J* 2002; **16**: 887–888.

59 Chen NJ, Mirtsos C, Suh D, Lu YC, Lin WJ, McKerlie C et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. *Nature* 2007; **446**: 203–207.

60 Kalant D, MacLaren R, Cui W, Samanta R, Monk PN, Laporte SA et al. C5L2 is a functional receptor for acylation-stimulating protein. *J Biol Chem* 2005; **280**: 23936–23944.

61 Gao H, Neff TA, Guo RF, Speyer CL, Sarma JV, Tomlins S et al. Evidence for a functional role of the second C5a receptor C5L2. *FASEB J* 2005; **19**: 1003–1005.

62 Rollins TE, Siciliano S, Kobayashi S, Cianciarulo DN, Bonilla-Argudo V, Collier K et al. Purification of the active C5a receptor from human polymorphonuclear leukocytes as a receptor-Gi complex. *Proc Natl Acad Sci USA* 1991; **88**: 971–975.

63 Amatruda III TT, Gerard NP, Gerard C, Simon MI. Specific interactions of chemoattractant factor receptors with G-proteins. *J Biol Chem* 1993; **268**: 10139–10144.

64 Johswich K, Klos A. C5L2—an anti-inflammatory molecule or a receptor for acylation stimulating protein (C3a-desArg)? *Adv Exp Med Biol* 2007; **598**: 159–180.

65 Perianayagam MC, Balakrishnan VS, King AJ, Pereira BJ, Jaber BL. C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway. *Kidney Int* 2002; **61**: 456–463.

66 Buhl AM, Avdi N, Worthen GS, Johnson GL. Mapping of the C5a receptor signal transduction network in human neutrophils. *Proc Natl Acad Sci USA* 1994; **91**: 9190–9194.

67 Mullmann TJ, Siegel MI, Egan RW, Billah MM. Complement C5a activation of phospholipase D in human neutrophils. A major route to the production of phosphatidates and diglycerides. *J Immunol* 1990; **144**: 1901–1908.

68 Huang R, Lian JP, Robinson D, Badwey JA. Neutrophils stimulated with a variety of chemoattractants exhibit rapid activation of p21-activated kinases (Paks): separate signals are required for activation and inactivation of paks. *Mol Cell Biol* 1998; **18**: 7130–7138.

69 Melendez AJ, Ibrahim FB. Antisense knockdown of sphingosine kinase 1 in human macrophages inhibits C5a receptor-dependent signal transduction, Ca^{2+} signals, enzyme release, cytokine production, and chemotaxis. *J Immunol* 2004; **173**: 1596–1603.

70 Kastl SP, Speidl WS, Kaun C, Rega G, Assadian A, Weiss TW et al. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation. *J Thromb Haemost* 2006; **4**: 1790–1797.

71 Mukherjee P, Pasinetti GM. Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. *J Neurochem* 2001; **77**: 43–49.

72 Gomez-Cambronero J, Di Fulvio M, Knapek K. Understanding phospholipase D (PLD) using leukocytes: PLD involvement in cell adhesion and chemotaxis. *J Leukoc Biol* 2007; **82**: 272–281.

73 Torres M, Forman HJ. Activation of several MAP kinases upon stimulation of rat alveolar macrophages: role of the NADPH oxidase. *Arch Biochem Biophys* 1999; **366**: 231–239.

74 Tsai HR, Yang LM, Tsai WJ, Chiou WF. Andrographolide acts through inhibition of ERK1/2 and Akt phosphorylation to suppress chemotactic migration. *Eur J Pharmacol* 2004; **498**: 45–52.

75 Guo RF, Riedemann NC, Ward PA. Role of C5a–C5aR interaction in sepsis. *Shock* 2004; **21**: 1–7.

76 Lo RK, Cheung H, Wong YH. Constitutively active Galpha16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism. *J Biol Chem* 2003; **278**: 52154–52165.

77 Prossnitz ER, Gilbert TL, Chiang S, Campbell JJ, Qin S, Newman W et al. Multiple activation steps of the N-formyl peptide receptor. *Biochemistry* 1999; **38**: 2240–2247.

78 Gerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S et al. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. *J Biol Chem* 2005; **280**: 39677–39680.

79 Huber-Lang MS, Younkin EM, Sarma JV, McGuire SR, Lu KT, Guo RF et al. Complement-induced impairment of innate immunity during sepsis. *J Immunol* 2002; **169**: 3223–3231.

80 Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo RF et al. Role of C5a in multiorgan failure during sepsis. *J Immunol* 2001; **166**: 1193–1199.

81 Seely AJ, Naud JF, Campisi G, Giannias B, Liu S, DiCarlo A et al. Alteration of chemoattractant receptor expression regulates human neutrophil chemotaxis in vivo. *Ann Surg* 2002; **235**: 550–559.

82 Riedemann NC, Guo RF, Bernacki KD, Reuben JS, Laudes IJ, Neff TA et al. Regulation by C5a of neutrophil activation during sepsis. *Immunity* 2003; **19**: 193–202.

83 Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. *FASEB J* 2003; **17**: 1003–1014.

84 Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. *Thromb Haemost* 1997; **77**: 394–398.

85 Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M et al. Local production of complement proteins in rheumatoid arthritis synovium. *Arthritis Rheum* 2002; **46**: 934–945.

86 Grant EP, Picarella D, Burwell T, Delaney T, Croci A, Avitahl N et al. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. *J Exp Med* 2002; **196**: 1461–1471.

87 Weissmann G. Pathogenesis of rheumatoid arthritis. *J Clin Rheumatol* 2004; **10**: S26–S31.

88 Sarma VJ, Huber-Lang M, Ward PA. Complement in lung disease. *Autoimmunity* 2006; **39**: 387–394.

89 Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. *J Immunol* 2003; **171**: 5514–5520.

90 Welch TR. Complement in glomerulonephritis. *Nat Genet* 2002; **31**: 333–334.

91 Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. *Arthritis Rheum* 1988; **31**: 632–641.

92 Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM. The role of the complement system in ischemia–reperfusion injury. *Shock* 2004; **21**: 401–409.

93 Marc MM, Korosec P, Kosnik M, Kern I, Flezar M, Suskovic S et al. Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma. *Am J Respir Cell Mol Biol* 2004; **31**: 216–219.

94 Muller-Ladner U, Jones JL, Wetsel RA, Gay S, Raine CS, Barnum SR. Enhanced expression of chemotactic receptors in multiple sclerosis lesions. *J Neurol Sci* 1996; **144**: 135–141.

95 Abe M, Shibata K, Akatsu H, Shimizu N, Sakata N, Katsuragi T et al. Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. *J Immunol* 2001; **167**: 4651–4660.

96 Speidl WS, Exner M, Amighi J, Kastl SP, Zorn G, Maurer G et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. *Eur Heart J* 2005; **26**: 2294–2299.

97 Gaca JG, Appel III JZ, Lukes JG, Gonzalez-Stawinski GV, Lesher A, Palestrant D et al. Effect of an anti-C5a monoclonal antibody indicates a prominent role for anaphylatoxin in pulmonary xenograft dysfunction. *Transplantation* 2006; **81**: 1686–1694.

98 Harkin DW, Romaschin A, Taylor SM, Rubin BB, Lindsay TF. Complement C5a receptor antagonist attenuates multiple organ injury in a model of ruptured abdominal aortic aneurysm. *J Vasc Surg* 2004; **39**: 196–206.

99 Younger JG, Sasaki N, Waite MD, Murray HN, Saleh EF, Ravage ZB et al. Detrimental effects of complement activation in hemorrhagic shock. *J Appl Physiol* 2001; **90**: 441–446.

100 Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. *J Clin Invest* 2003; **112**: 1644–1654.

101 Allegretti M, Moriconi A, Beccari AR, Di Bitondo R, Bizzarri C, Bertini R et al. Targeting C5a: recent advances in drug discovery. *Curr Med Chem* 2005; **12**: 217–236.

102 de Laszlo SE, Allen EE, Li B, Ondeyka D, Rivero R, Malkowitz L et al. A nonpeptidic agonist ligand of the human C5a receptor: synthesis, binding affinity optimization and functional characterization. *Bioorg Med Chem Lett* 1997; **7**: 213–218.

103 Waters SM, Brodbeck RM, Steflik J, Yu J, Baltazar C, Peck AE et al. Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule antagonist interaction. *J Biol Chem* 2005; **280**: 40617–40623.

104 Pellas TC, Boyar W, van Oostrum J, Wasvary J, Fryer LR, Pastor G et al. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo. *J Immunol* 1998; **160**: 5616–5621.

105 Konteatis ZD, Siciliano SJ, Van Riper G, Molineaux CJ, Pandya S, Fischer P et al. Development of C5a receptor antagonists. Differential loss of functional responses. *J Immunol* 1994; **153**: 4200–4205.

106 Paczkowski NJ, Finch AM, Whitmore JB, Short AJ, Wong AK, Monk PN et al. Pharmacological characterization of antagonists of the C5a receptor. *Br J Pharmacol* 1999; **128**: 1461–1466.

107 Wong AK, Finch AM, Pierens GK, Craik DJ, Taylor SM, Fairlie DP. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. *J Med Chem* 1998; **41**: 3417–3425.

108 Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. *J Med Chem* 1999; **42**: 1965–1974.

109 Lee H, Zahra D, Vogelzang A, Newton R, Thatcher J, Quan A et al. Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. *Nat Biotechnol* 2006; **24**: 1279–1284.

110 Huang L, Sato AK, Sachdeva M, Fleming T, Townsend S, Dransfield DT. Discovery of human antibodies against the C5aR target using phage display technology. *J Mol Recognit* 2005; **18**: 327–333.

111 Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. *Mol Immunol* 1996; **33**: 1389–1401.

112 Fung M, Lu M, Fure H, Sun W, Sun C, Shi NY et al. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage. *Clin Exp Immunol* 2003; **133**: 160–169.

113 Sumichika H. C5a receptor antagonists for the treatment of inflammation. *Curr Opin Investig Drugs* 2004; **5**: 505–510.

114 Riley RD, Sato H, Zhao ZQ, Thourani VH, Jordan JE, Fernandez AX et al. Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization. *J Thorac Cardiovasc Surg* 2000; **120**: 350–358.

115 Heller T, Hennecke M, Baumann U, Gessner JE, zu Vilsendorf AM, Baensch M et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. *J Immunol* 1999; **163**: 985–994.

116 Strachan AJ, Woodruff TM, Haaima G, Fairlie DP, Taylor SM. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. *J Immunol* 2000; **164**: 6560–6565.

117 Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP *et al.* Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. *Arthritis Rheum* 2002; **46**: 2476–2485.

118 Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. *Kidney Int* 2003; **63**: 134–142.

119 Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia–reperfusion in rats. *J Surg Res* 2004; **116**: 81–90.

120 Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. *Eur J Immunol* 2005; **35**: 2496–2506.

121 Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, McGuire SR, Laudes IJ *et al.* Protection of innate immunity by C5aR antagonist in septic mice. *FASEB J* 2002; **16**: 1567–1574.

122 Vergunst CE, Gerlag DM, Dinant H, Schulz L, Vinkenoog M, Smeets TJ *et al.* Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. *Rheumatology* 2007; **46**: 1773–1778.

123 Carter PJ. Potent antibody therapeutics by design. *Nat Rev* 2006; **6**: 343–357.

124 Presta LG. Selection, design, and engineering of therapeutic antibodies. *J Allergy Clin Immunol* 2005; **116**: 731–736; quiz 737.

125 Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. *Nat Biotechnol* 2005; **23**: 1073–1078.

126 Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N *et al.* Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. *J Clin Invest* 1997; **99**: 178–184.

127 Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. *Annu Rev Immunol* 1994; **12**: 775–808.

128 Avlani VA, Gregory KJ, Morton CJ, Parker MW, Sexton PM, Christopoulos A. Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. *J Biol Chem* 2007; **282**: 25677–25686.

129 Scarselli M, Li B, Kim SK, Wess J. Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation. *J Biol Chem* 2007; **282**: 7385–7396.

130 Wurch T, Colpaert FC, Pauwels PJ. Chimeric receptor analysis of the ketanserin binding site in the human 5-Hydroxytryptamine1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist binding. *Mol Pharmacol* 1998; **54**: 1088–1096.

131 Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N *et al.* Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. *J Exp Med* 1997; **186**: 1373–1381.

132 Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA *et al.* Arthritis critically dependent on innate immune system players. *Immunity* 2002; **16**: 157–168.

133 Gressner O, Meier U, Hillebrandt S, Wasmuth HE, Köhl J, Sauerbruch T *et al.* Gc-globulin concentrations and C5 haplotype-tagging polymorphisms contribute to variations in serum activity of complement factor C5. *Clin Biochem* 2007; **40**: 771–775.

134 Verschure PJ, Van Noorden CJ. The effects of interleukin-1 on articular cartilage destruction as observed in arthritic diseases, and its therapeutic control. *Clin Exp Rheumatol* 1990; **8**: 303–313.

135 Pelletier JP, Roughley PJ, DiBattista JA, McCollum R, Martel-Pelletier J. Are cytokines involved in osteoarthritic pathophysiology? *Semin Arthritis Rheum* 1991; **20**: 12–25.

136 Mizuno M. A review of current knowledge of the complement system and the therapeutic opportunities in inflammatory arthritis. *Curr Med Chem* 2006; **13**: 1707–1717.